Aprea Therapeutics enters $1.0M at-the-market equity distribution agreement with H.C. Wainwright

Aprea Therapeutics, Inc.

Enters ATM agreement to sell up to $1.0M of common stock through H.C. Wainwright as agent.
Commission of 3.0% of gross proceeds; net proceeds for general corporate purposes including trials.
Company not obligated to sell any shares; offering made under Form S-3 filed Jan 26, 2024.
At-the-market offering allows stock sales at prevailing market prices over time.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aprea Therapeutics, Inc. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $1.0 million (effective 2024-01-26).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: up to $1.0 million
Effective: 2024-01-26

Exact text from the filing

On January 26, 2024, Aprea Therapeutics, Inc. (the “Company”) entered into an at the market offering agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “HCW”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-006976

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.